{
    "clinical_study": {
        "@rank": "75626", 
        "arm_group": [
            {
                "arm_group_label": "Child Pugh A", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who are included Child Pugh A"
            }, 
            {
                "arm_group_label": "Child Pugh B", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who are included Child Pugh B"
            }, 
            {
                "arm_group_label": "Subject who are matched Child Pugh A", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to the Subjects who are matched Child Pugh A"
            }, 
            {
                "arm_group_label": "Subject who are matched Child Pugh B", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to the subjects who are matched Child Pugh B"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with\n      impaired hepatic function compared with normal hepatic function."
        }, 
        "brief_title": "A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Dysfunction", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "A Phase 1, Non-randomized, Open, Parallel-Group study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "A. Inclusion Criteria\n\n        [The subjects with impaired hepatic function]\n\n          1. The subjects who are 19 to 64 years old\n\n          2. The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh\n             A or B\n\n          3. Body Weight \u2265 55kg\n\n          4. If females, Negative for pregnancy test at the screening and pre dose of Day 1\n\n          5. The subjects who agreed with performing contraception during the study\n\n          6. The subjects who agreed with written informed consent\n\n        [The subjects with normal hepatic function]\n\n          1. The subjects who are 19 to 64 years old\n\n          2. The subjects who are matched impaired hepatic function by gender, age(\u00b1 5years) and\n             body weight(\u00b1 10kg)\n\n          3. If females, Negative for pregnancy test at the screening and pre dose of Day 1\n\n          4. The subjects who agreed with performing contraception during the study\n\n          5. The subjects who agreed with written informed consent\n\n        B. exclusion criteria\n\n        [The subjects with impaired hepatic function]\n\n          1. The subjects with impaired hepatic function as Child-Pugh C\n\n          2. The subjects had a portosystemic shunt surgery\n\n          3. The subjects had a liver transplantation or unsuitable for the study by the\n             investigator's judgement(for examples, hepatic encephalopathy, risk of esophageal\n             varixes bleeding, stroke, heart failure, cancer etc.)\n\n          4. The subjects have a gastrointestinal disease or surgery which can be effected in\n             absorption of Investigational product\n\n          5. The subjects who took drugs or medicine which can be effected in metabolism of\n             Cytochrome P450 within 14days prior to Day 1\n\n          6. Positive for anti-HIV Ab or venereal disease research laboratory etc.\n\n        [The subjects with normal hepatic function]\n\n          1. The subjects with liver disease or abnormal Laboratory test(Asparate transaminase\n             >1.25 fold of upper normal limit, Alanine transaminase>1.25 fold of upper normal\n             limit, Total bilirubin >1.5 fold of upper normal limit)\n\n          2. The subjects have a gastrointestinal disease or surgery which can be effected in\n             absorption of Investigational product\n\n          3. Estimated Glomerular filtration rate < 60 mL/min/1.73m2 by Modification of Diet in\n             Renal Disease formula\n\n          4. Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease\n             research laboratory\n\n          5. The subjects with high blood pressure or low blood pressure(systolic blood pressure\n             >150mmHg or <100mmHg, diastolic blood pressure>90mmHg or <60mmHg)\n\n          6. The subjects who took drugs or medicine which can be effected in metabolism of\n             Cytochrome P450 within 14days prior to Day 1 etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005744", 
            "org_study_id": "19HI13018"
        }, 
        "intervention": {
            "arm_group_label": [
                "Child Pugh A", 
                "Child Pugh B", 
                "Subject who are matched Child Pugh A", 
                "Subject who are matched Child Pugh B"
            ], 
            "description": "CKD-501 0.5mg, PO(per oral), once", 
            "intervention_name": "CKD-501", 
            "intervention_type": "Drug", 
            "other_name": "Lobeglitazone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "CKD-501", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "minspark@yuhs.ac", 
                "last_name": "Min Soo Park, Ph.D. M.D", 
                "phone": "+82 2 2228 0400"
            }, 
            "facility": {
                "address": {
                    "city": "Soeul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Yonsei University Severance Hospital"
            }, 
            "investigator": {
                "last_name": "Min Soo Park, Ph.D. M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function", 
        "other_outcome": [
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 days"
            }, 
            {
                "measure": "Physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 days"
            }, 
            {
                "measure": "Laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 days"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 days"
            }
        ], 
        "overall_official": {
            "affiliation": "Yonsei University Severance Hospital", 
            "last_name": "Min Soo Park, Ph.D. M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sampling timepoint(hours)\n: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48", 
            "measure": "Area Under the Concentration(last) and Cmax of CKD-501", 
            "safety_issue": "No", 
            "time_frame": "0 to 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005744"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Sampling timepoint(hours)\n: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48", 
                "measure": "Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "0 to 48 hours"
            }, 
            {
                "description": "sampling timepoint(hours)\n: 1, 8", 
                "measure": "Fraction Unbound of CKD-501 and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "1 and 8 hours"
            }, 
            {
                "description": "sampling timepoint(hours)\n: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48", 
                "measure": "Area Under the Concentration(last) and Cmax of the metabolite", 
                "safety_issue": "No", 
                "time_frame": "o to 48 hours"
            }, 
            {
                "description": "sampling timepoint(hours)\n: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48", 
                "measure": "Metabolic ratio(metabolite/CKD-501)", 
                "safety_issue": "No", 
                "time_frame": "0 to 48 hours"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}